^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Myelodysplastic Syndrome

    16h
    A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment (clinicaltrials.gov)
    P1, N=30, Recruiting, Servier Bio-Innovation LLC
    Trial initiation date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 R132
    |
    Tibsovo (ivosidenib)
    19h
    Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1, N=58, Terminated, Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting --> Terminated; Adjusted the product development strategy.
    Trial termination
    23h
    WATCH Tranfuse: WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Exploratory Study to Improve Quality of Life and the Efficacy of Transfusion Supportive Care in People With Blood Cancers Undergoing Treatment (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, University of Oxford
    New trial • HEOR
    23h
    A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy (clinicaltrials.gov)
    P=N/A, N=320, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    1d
    Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study (clinicaltrials.gov)
    P=N/A, N=30, Completed, Ohio State University Comprehensive Cancer Center | Active, not recruiting --> Completed
    Trial completion
    1d
    The ASH HematOmics Program supports integrative analysis of genomic and clinical data in hematologic diseases. (PubMed, Blood)
    We illustrate four use cases of ASHOP: (1) stratification of DUX4-rearranged B-cell leukemias into Early/Multipotent and Committed subgroups with distinct outcomes, (2) characterization of HOXA/HOXB expression patterns in acute myeloid leukemias, (3) correlating mutational burden with mismatch repair deficiency and mutational signatures, (4) investigation of TP53 alteration landscape. ASHOP is an open-access resource to inform genomic and transcriptomic data interpretation for hematologic malignancies, and will expand to support additional diseases and data modalities from the ASH community.
    Clinical data • Journal • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • DUX4 (Double Homeobox 4)
    |
    TP53 mutation
    1d
    Reduced STAG2 expression in myelodysplastic neoplasms and acute myeloid leukemia myelodysplasia-related: a potential biomarker associated with aneuploidy and disease progression. (PubMed, Front Cell Dev Biol)
    Our findings suggest that reduced STAG2 protein expression plays a relevant role in MDS pathogenesis. Immunohistochemical assessment of STAG2 may be incorporated into the clinical workflows as a potential diagnostic and prognostic biomarker, as well as indicate therapeutic targets, particularly in association with complex karyotypes and trisomy 8.
    Journal
    |
    STAG2 (Stromal Antigen 2)
    3d
    Genomic Landscape and Clinical Outcomes of Advanced Pediatric Myelodysplastic Syndromes. (PubMed, Eur J Haematol)
    In advanced pediatric MDS, HSCT was associated with improved survival, whereas PTPN11 mutations emerged as an adverse prognostic factor.
    Clinical data • Journal
    |
    ETV6 (ETS Variant Transcription Factor 6) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • SETBP1 (SET Binding Protein 1) • GATA2 (GATA Binding Protein 2)
    4d
    A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms (clinicaltrials.gov)
    P1, N=155, Recruiting, Janssen Research & Development, LLC | N=100 --> 155
    Enrollment change • First-in-human
    |
    Venclexta (venetoclax)
    4d
    FMT: Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cell Transplant: A Pilot Study (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, University Health Network, Toronto
    New trial
    4d
    Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia (clinicaltrials.gov)
    P1/2, N=20, Active, not recruiting, Nationwide Children's Hospital | Trial completion date: Jan 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    4d
    Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML (clinicaltrials.gov)
    P1/2, N=52, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • MECOM (MDS1 And EVI1 Complex Locus)
    |
    pelcitoclax (APG-1252)